Literature DB >> 2083945

Heterozygosity effects in studies of genetic markers and disease.

L Beckman1, N Fröhlander.   

Abstract

Examples were discussed where heterozygosity was associated with increased or decreased disease risks and where the apparent mechanism is direct functional involvement of gene products and not linkage disequilibrium. Special attention was paid to the impact of Hp (haptoglobin) heterozygosity on a number of different multifactorial disorders. When phenotype distributions in patients show large deviations from the Hardy-Weinberg equilibrium significant differences between patients and controls may be found concerning phenotype distributions but not with respect to the frequencies of alleles and phenotypic factors. The common method of studying ratios of phenotypic factors by pooling homo- and heterozygotes is in principle a conservative approach which tends to underestimate the strength of associations and to obscure heterozygosity effects. A significant deviation from the Hardy-Weinberg equilibrium in a marker system examined in a group of patients is in itself a sensitive indicator of phenotypic association with the disease in question.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083945     DOI: 10.1159/000153955

Source DB:  PubMed          Journal:  Hum Hered        ISSN: 0001-5652            Impact factor:   0.444


  2 in total

1.  Genetic markers associated with high versus low performance on episodic memory tasks.

Authors:  L G Nilsson; C Sikström; R Adolfsson; K Erngrund; P O Nylander; L Beckman
Journal:  Behav Genet       Date:  1996-11       Impact factor: 2.805

2.  A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4 µg mL-1 at the time of loss of consciousness.

Authors:  Zhuoling Zheng; Faling Xue; Zhongxing Wang; Jiali Li; Haini Wang; Yongqi He; Lingyi Zhang; Wudi Ma; Caibin Zhang; Yanping Guan; Fang Ye; Yongzi Wen; Xiaoyan Li; Min Huang; Wenqi Huang
Journal:  Pharmacogenomics J       Date:  2022-01-22       Impact factor: 3.245

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.